PRKCE and obesity disorder: MGAT1 inhibitors suppress the conversion of monoacylglycerols to DAGs; normalize glucose tolerance; decrease PKCε activation; improve hepatic insulin signaling. MGAT2 inhibitors prevent diet-induced obesity and hepatic steatosis